Neuro-Oncology News

It’s only the beginning.

PHILADELPHIA — In this video, Michael Fisher, MD, highlights a keynote presentation given by Charles Limoli, PhD, at the International Symposium on Pediatric Neuro-Oncology.

PHILADELPHIA — In this video, Michael Fisher, MD, highlights the sessions and presentations at the International Symposium on Pediatric Neuro-Oncology.

Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.

CHICAGO — Time between therapy regimens can safely be offered to certain children with cancer to promote quality of life and explore goals of care without negatively affecting survival, according to data presented at ASCO Annual Meeting.

The FDA granted accelerated approval to repotrectinib for the treatment of adults and children 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion.

Jonathan T. Yang, MD, PhD, has been appointed associate vice chair for clinical research and developmental therapeutics in the department of radiation oncology at NYU Langone Health’s Perlmutter Cancer Center.

Participation in cancer-related clinical trials could increase dramatically if researchers screened and recruited individuals using routine care patient-reported outcomes, according to results published in JAMA Oncology.

An mRNA cancer vaccine developed at University of Florida may have the ability to reprogram the immune system against glioblastoma, findings of a first-in-human trial showed.

Patients participating in clinical trials for anticancer drugs do not gain a survival benefit compared with individuals who received routine care, according to study results published in JAMA.